Top five ophthalmology stories in June

The most frequently viewed ophthalmology articles on Healio.com/OSN in June included journal summaries, FDA approvals and shakeups in business leadership.

Here are the top five most-viewed stories from the month.

1. Lampalizumab reduces geographic atrophy lesion progression

The MAHALO study found monthly lampalizumab reduced geographic atrophy lesion area progression by 20% compared with a sham control. Read more.

2. FDA approves ReNeuron’s cryopreserved formulation of retinal stem cell therapy candidate

Patients with retinitis pigmentosa are now being treated with the formulation in a phase 1/2 clinical trial. Read more.

3. Novartis’ RTH258 for wet AMD meets endpoints in phase 3 trials

The HAWK and HARRIER trials studied the non-inferiority of RTH258 (brolucizumab, 6 mg) vs. Eylea (aflibercept, Regeneron). Read more.

4. John Snisarenko named Shire’s group vice president, head of ophthalmics

Snisarenko has 30 years of experience, including most recently serving as vice president of sales and marketing for Genentech’s rheumatology franchise. Read more.

5. Jonathan Talamo, MD, named chief medical officer of Johnson & Johnson Vision

Talamo has more than 25 years of ophthalmic experience and most recently served as chief medical officer of Ocular Therapeutix. Read more.